CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine

Mycobacterium tuberculosis is a major human pathogen, and new vaccines are needed to prevent transmission. Mucosal vaccination may confer protection against M. tuberculosis by stimulating tissue-resident memory (T-RM) CD4(+) T cells in the lungs. The chemokine receptor CXCR3 promotes lung recruitment of T cells, but its role in T-RM development is unknown. This study demonstrates the recombinant influenza A virus vaccine PR8.p25, expressing the immunodominant M. tuberculosis T cell epitope p25, induces CXCR3 expression on p25-specific CD4(+) T cells in the lungs so that the majority of vaccine-induced CD4(+) T-RM expresses CXCR3 at 6 weeks. However, CXCR3(-/-) mice developed equivalent antigen-specific CD4(+) T cell responses to wild-type (WT) mice following PR8.p25, and surprisingly retained more p25-specific CD4(+) T-RM in the lungs than WT mice at 6 weeks. The adoptive transfer of CXCR3(-/-) and WT P25 T cells into WT mice revealed that the initial recruitment of vaccine-induced CD4(+) T cells into the lungs was independent of CXCR3, but by 6 weeks, CXCR3-deficient P25 T cells, and especially CXCR3(-/-) T-RM, were significantly reduced compared to CXCR3-sufficient P25 T cells. Therefore, although CXCR3 was not essential for CD4(+) T-RM recruitment or retention, it provided a competitive advantage for the induction of M. tuberculosis-specific CD4(+) T-RM in the lungs following pulmonary immunization.